Clinical Trial Update: Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating high-dose nilotinib with high-dose imatinib in Gastrointestinal Stromal Tumors refractive to imatinib, which was terminated with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Gleevec (Imatinib)
• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: TERMINATED | Results posted: 2014-03-26